SandboxAQ, a provider of quantitative AI solutions for medical applications, has partnered with Mayo Clinic to investigate the combined use of electrocardiography (ECG) and magnetocardiography (MCG) technologies in the diagnosis and monitoring of amyloidosis.
The collaboration focuses on using these tools to characterise disease progression and assess treatment responses.
Amyloidosis is a condition marked by the accumulation of abnormal protein deposits in tissues and organs, including the heart.
Current diagnostic tools often face challenges in detecting subtle changes in cardiac function, which can delay intervention and hinder effective management, said SandboxAQ.
By combining the established capabilities of ECG with the sensitivity of MCG, the collaboration seeks to create a non-invasive diagnostic method that provides detailed insights into the electrical and magnetic activity of the heart.
SandboxAQ CEO Jack Hidary said: “This collaboration represents a significant milestone in our mission to leverage quantitative AI to revolutionise diagnostic accuracy and speed and improve patient care.”
SandboxAQ’s AQMed division general manager Kit Yee Au-Yeung said: “By uniting AQMed’s technical innovation with Mayo Clinic’s renowned research and clinical excellence, we aim to make a meaningful impact on the lives of amyloidosis patients across the globe in the near future.”
The partnership builds on an ongoing initiative in which Mayo Clinic is testing the SandboxAQ MCG device and AI technologies in clinical settings in Rochester, Minnesota.
The expanded collaboration will begin with joint research studies to assess the feasibility of integrating ECG and MCG technologies for enhanced diagnostic accuracy.
The study’s findings are expected to provide improved methods for tracking disease progression and treatment effectiveness in amyloidosis patients.
Additionally, the research may have implications for other cardiac conditions that require non-invasive diagnostic and monitoring techniques.
Earlier this month, Mayo Clinic Laboratories partnered with Singapore-based molecular diagnostics firm Lucence to enhance the availability of advanced cancer testing services.